{
    "xml": "<topic id=\"PHP4072\" outputclass=\"drug\" rev=\"1.19\" type=\"drug\" namespace=\"/drugs/insulin-glargine\" basename=\"insulin-glargine\" title=\"INSULIN GLARGINE\">\n<title>INSULIN GLARGINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_265\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/insulin\">Insulin</xref>\n</p>\n<data name=\"vtmid\">126212009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_654406860\" title=\"Insulins\">Insulins</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34635\" title=\"INSULINS\" namespace=\"/drug-classes/insulins\">INSULINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">Recombinant human insulin analogue&#8212;long acting</p>\r\n</body>\n<topic id=\"PHP42024\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/insulin-glargine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Diabetes mellitus</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 2&#8211;17 years</p>\n<p>According to requirements.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>According to requirements.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42019\" outputclass=\"interactions\" rev=\"1.6\" parent=\"/drugs/insulin-glargine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antidiabetics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42008\" outputclass=\"pregnancy\" parent=\"/drugs/insulin-glargine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin is recommended where longer-acting insulins are needed; insulin detemir may also be considered.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41970\" outputclass=\"nationalFunding\" rev=\"1.11\" parent=\"/drugs/insulin-glargine\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (March 2013) that insulin glargine is accepted for restricted use within NHS Scotland for the treatment of type 1 diabetes:</p>\n<ul>\n<li>in those who are at risk of or experience unacceptable frequency or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with other insulins</li>\n<li>as a once daily insulin therapy for patients who require a carer to administer their insulin</li>\n</ul>\n<p>It is <b>not</b> recommended for routine use in patients with type 2 diabetes unless they suffer from recurrent episodes of hypoglycaemia or require assistance with their insulin injections.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP4072-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/insulin-glargine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76289\" title=\"Solution for injection\" namespace=\"/drugs/insulin-glargine/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78107\" namespace=\"/treatment-summaries/insulins-and-anti-diabetic-drugs\" title=\"Insulins and anti-diabetic drugs\" count=\"6\" rel=\"backlink\">Insulins and anti-diabetic drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78351\" namespace=\"/treatment-summaries/diabetic-ketoacidosis-management\" title=\"Diabetic ketoacidosis, management\" count=\"1\" rel=\"backlink\">Diabetic ketoacidosis, management</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_265\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/insulin\" title=\"Insulin\" count=\"1\" rel=\"link\">Insulin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34635\" namespace=\"/drug-classes/insulins\" title=\"INSULINS\" count=\"1\" rel=\"link\">INSULINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76289\" namespace=\"/drugs/insulin-glargine/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP4072",
    "outputclass": "drug",
    "rev": "1.19",
    "type": "drug",
    "namespace": "/drugs/insulin-glargine",
    "basename": "insulin-glargine",
    "title": "INSULIN GLARGINE",
    "interactants": [
        {
            "id": "bnf_int_265",
            "label": "Insulin"
        }
    ],
    "vtmid": "126212009",
    "drugClassification": [
        "Insulins"
    ],
    "inheritsFromClass": [
        "INSULINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Recombinant human insulin analogue&#8212;long acting"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Diabetes mellitus",
                        "html": "Diabetes mellitus"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "child": [
                    {
                        "textContent": "According to requirements.",
                        "html": "<p>According to requirements.</p>",
                        "ageGroup": "2&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "According to requirements.",
                        "html": "<p>According to requirements.</p>"
                    }
                ]
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antidiabetics).",
                "html": "<p>Appendix 1 (antidiabetics).</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin is recommended where longer-acting insulins are needed; insulin detemir may also be considered.",
                "html": "<p>Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin is recommended where longer-acting insulins are needed; insulin detemir may also be considered.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (March 2013) that insulin glargine is accepted for restricted use within NHS Scotland for the treatment of type 1 diabetes: in those who are at risk of or experience unacceptable frequency or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with other insulins as a once daily insulin therapy for patients who require a carer to administer their insulin It is not recommended for routine use in patients with type 2 diabetes unless they suffer from recurrent episodes of hypoglycaemia or require assistance with their insulin injections.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (March 2013) that insulin glargine is accepted for restricted use within NHS Scotland for the treatment of type 1 diabetes:</p> <ul> <li>in those who are at risk of or experience unacceptable frequency or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with other insulins</li> <li>as a once daily insulin therapy for patients who require a carer to administer their insulin</li> </ul> <p>It is <b>not</b> recommended for routine use in patients with type 2 diabetes unless they suffer from recurrent episodes of hypoglycaemia or require assistance with their insulin injections.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76289",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78107",
                "label": "Insulins and anti-diabetic drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78351",
                "label": "Diabetic ketoacidosis, management",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_265",
                "label": "Insulin",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34635",
                "label": "INSULINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76289",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}